Login to Your Account



ADVANCED THERAPIES INVESTOR DAY

Experts argue merits of allogeneic, autologous heart failure cell therapies

By Nuala Moran
Staff Writer

Saturday, November 15, 2014

LONDON – The race to deliver a commercial stem cell therapy for treating heart failure is heating up with two products now well advanced in phase III trials. However, the question of whether allogeneic or autologous cells represent the best approach remains unresolved.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription